Literature DB >> 25822554

Diagnosis and management of kawasaki disease.

Aaron Saguil1, Matthew Fargo2, Scott Grogan2.   

Abstract

Kawasaki disease is an acute, systemic vasculitis that predominantly affects patients younger than five years. It represents the most prominent cause of acquired coronary artery disease in childhood. In the United States, 19 per 100,000 children younger than five years are hospitalized with Kawasaki disease annually. According to U.S. and Japanese guidelines, Kawasaki disease is a clinical diagnosis. Classic (typical) Kawasaki disease is diagnosed based on the presence of a fever lasting five or more days, accompanied by four out of five findings: bilateral conjunctival injection, oral changes such as cracked and erythematous lips and strawberry tongue, cervical lymphadenopathy, extremity changes such as erythema or palm and sole desquamation, and polymorphous rash. Incomplete (atypical) Kawasaki disease occurs in persons with fever lasting five or more days and with two or three of these findings. Transthoracic echocardiography is the diagnostic imaging modality of choice to screen for coronary aneurysms, although other techniques are being evaluated for diagnosis and management. Treatment for acute disease is intravenous immunoglobulin and aspirin. If there is no response to treatment, patients are given a second dose of intravenous immunoglobulin with or without corticosteroids or other adjunctive treatments. The presence and severity of coronary aneurysms and obstruction at diagnosis determine treatment options and the need, periodicity, and intensity of long-term cardiovascular monitoring for potential atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25822554

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  32 in total

1.  Oxidised Low-Density Lipoprotein and Its Receptor-Mediated Endothelial Dysfunction Are Associated with Coronary Artery Lesions in Kawasaki Disease.

Authors:  Yue-E He; Hui-Xian Qiu; Rong-Zhou Wu; Xing Rong; Hai-Tang Xu; Ru-Lian Xiang; Mao-Ping Chu
Journal:  J Cardiovasc Transl Res       Date:  2019-08-19       Impact factor: 4.132

Review 2.  The Roles of Genetic Factors in Kawasaki Disease: A Systematic Review and Meta-analysis of Genetic Association Studies.

Authors:  Xiaochuan Xie; Xiaohan Shi; Meilin Liu
Journal:  Pediatr Cardiol       Date:  2017-11-02       Impact factor: 1.655

3.  Retrospective study of the course, treatment and long-term follow-up of Kawasaki disease: a single-center experience from Poland.

Authors:  Aleksandra Stasiak; Elżbieta Smolewska
Journal:  Rheumatol Int       Date:  2019-03-22       Impact factor: 2.631

4.  Mesenteric Lymphadenitis Presenting as Acute Abdomen in a Child with Multisystem Inflammatory Syndrome.

Authors:  Evangelos Blevrakis; Eleni Vergadi; Maria Stefanaki; Iris Alexiadi-Oikonomou; Glykeria Rouva; Ioannis Germanakis; Emmanouil Galanakis
Journal:  Infect Dis Rep       Date:  2022-06-06

5.  Refractory Kawasaki Disease Presenting With Erythema at Bacille Calmette-Guérin Inoculation Site: A Paediatric Case Report.

Authors:  Vijayakumary Thadchanamoorthy; Kavinda Dayasiri
Journal:  Cureus       Date:  2020-10-13

6.  Desquamation in Kawasaki Disease.

Authors:  Ling-Sai Chang; Ken-Pen Weng; Jia-Huei Yan; Wan-Shan Lo; Mindy Ming-Huey Guo; Ying-Hsien Huang; Ho-Chang Kuo
Journal:  Children (Basel)       Date:  2021-04-21

Review 7.  Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.

Authors:  M A Bordea; C Costache; A Grama; A I Florian; I Lupan; G Samasca; D Deleanu; P Makovicky; P Makovicky; K Rimarova
Journal:  Physiol Res       Date:  2022-01-19       Impact factor: 1.881

Review 8.  Coronary Vasculitis.

Authors:  Tommaso Gori
Journal:  Biomedicines       Date:  2021-05-31

Review 9.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.834

10.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.